Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $650 thousand versus the consensus estimate of $1.85 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.